\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ patient\\ will\\ require\\ followup\\ with\\ his\\ pcm\\ for\\ cr\\ and\\ ct\\ as\\ indicated\\.\ \(0\)\
\-\ pleural\\ calcifications\\ at\\ bilateral\\ post\\/lat\\ and\\ base\\ predominately\\ at\\ middle\\ and\\ lower\\ chest\\.\ \(0\)\
\-\ holly\\ leaf\\ appearance\\.\ \(0\)\
\-\ asbestos\\-related\\ pleural\\ disease\ \(1\)\
\-\ sequella\\ of\\ prior\\ hemothorax\\,\\ empyema\\,\\ surgery\ \(0\)\
\-\ tuberculosis\ \(73\)\
\-\ asbestos\\-related\\ pleural\\ disease\ \(1\)\
\-\ 60\\ y\\.o\\.\\ man\\ with\\ rib\\ contusion\\ \\-\\ r\\/o\\ fracture\\.\ \(1\)\
\-\ focal\\ pleural\\ plaques\\ are\\ the\\ most\\ common\\ manifestation\\ of\\ asbestos\\ exposure\\ and\\ develop\\ 20\\-30\\ years\\ after\\ exposure\\.\\ \\ most\\ often\\ focal\\ interrupted\\ areas\\ of\\ plural\\ thickening\\ located\\ in\\ the\\ posterolateral\\ middle\\ and\\ lower\\ chest\\ bilaterally\\ and\\ represent\\ hyalinized\\ collagen\\ in\\ submesothelial\\ layer\\ of\\ parietal\\ pleura\\.\\ the\\ mediastinal\\ pleural\\ surface\\ and\\ costophrenic\\ sulci\\ are\\ characteristically\\ spared\\.\\ \\ \ \(0\)\
\-\ diffuse\\ pleural\\ thickening\\ is\\ less\\ common\\ than\\ focal\\ plaques\\,\\ are\\ associated\\ with\\ round\\ atelectasis\\,\\ and\\ may\\ cause\\ respiratory\\ symptoms\\.\\ \\ \ \(0\)\
\-\ pleural\\ calcifications\\,\\ as\\ in\\ this\\ case\\,\\ in\\ the\\ absence\\ of\\ hemothorax\\,\\ empyema\\,\\ tuberculosis\\ or\\ previous\\ surgery\\ is\\ pathognomonic\\.\\ \\ this\\ requires\\ greater\\ than\\ 20\\ years\\ to\\ develop\\.\\ \\ \ \(0\)\
\-\ an\\ early\\ sign\\ of\\ asbestos\\-related\\ pleural\\ disease\\ are\\ pleural\\ effusions\\ but\\ as\\ with\\ pleural\\ calcifications\\ other\\ causes\\ must\\ be\\ excluded\\.\\ \\ these\\ include\\ malignant\\ mesothelioma\\,\\ bronchogenic\\ carcinoma\\ and\\ tuberculosis\\.\\ \\ \ \(0\)\
\-\ malignancy\\ in\\ asbestos\\-related\\ disease\ \(0\)\
\-\ 7000x\\ increased\\ incidence\\ of\\ mesothelioma\\;\\ however\\,\\ this\\ equals\\ a\\ 10\\ \\%\\ lifetime\\ risk\\,\\ \\>30yrs\\ after\\ exposure\\.\ \(1\)\
\-\ other\\ associated\\ increase\\ risks\\ include\\ 7x\\ increase\\ in\\ bronchogenic\\ carcinoma\\ and\\ 3x\\ increase\\ in\\ gastrointestinal\\ neoplasia\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pleural\\:\\ 0\\.45824444506648115\ \(0\)\
\-\ asbestos\\:\\ 0\\.35197925954871967\ \(0\)\
\-\ exposure\\:\\ 0\\.17355312739901868\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.16070471256197577\ \(0\)\
\-\ increase\\:\\ 0\\.1465978391241175\ \(0\)\
\-\ hemothorax\\:\\ 0\\.13552310413570523\ \(0\)\
\-\ mesothelioma\\:\\ 0\\.1348663614477843\ \(0\)\
\-\ calcifications\\:\\ 0\\.13327863666374115\ \(0\)\
\-\ empyema\\:\\ 0\\.1313010174480344\ \(0\)\
\-\ and\\:\\ 0\\.12578569172111134\ \(0\)\
\-\ plaques\\:\\ 0\\.12283059546410621\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.1170619367254008\ \(0\)\
\-\ develop\\:\\ 0\\.1120760226749191\ \(0\)\
\-\ focal\\:\\ 0\\.10923364129798101\ \(0\)\
\-\ in\\:\\ 0\\.10600182076653768\ \(0\)\
\-\ disease\\:\\ 0\\.1022085519479917\ \(0\)\
\-\ submesothelial\\:\\ 0\\.0973484747239\ \(0\)\
\-\ 7000x\\:\\ 0\\.0973484747239\ \(0\)\
\-\ 30yrs\\:\\ 0\\.0973484747239\ \(0\)\
\-\ 7x\\:\\ 0\\.09302166465751878\ \(0\)\
\-\ are\\:\\ 0\\.09239347153491874\ \(0\)\
\-\ holly\\:\\ 0\\.08995174405988815\ \(0\)\
\-\ sequella\\:\\ 0\\.08995174405988815\ \(0\)\
\-\ middle\\:\\ 0\\.08705788444048618\ \(0\)\
\-\ hyalinized\\:\\ 0\\.08562493399350693\ \(0\)\
\-\ equals\\:\\ 0\\.08562493399350693\ \(0\)\
\-\ leaf\\:\\ 0\\.08397995715116378\ \(0\)\
\-\ 3x\\:\\ 0\\.08397995715116378\ \(0\)\
\-\ of\\:\\ 0\\.08338743329155453\ \(0\)\
\-\ thickening\\:\\ 0\\.08282520859194542\ \(0\)\
\-\ plural\\:\\ 0\\.08255501339587631\ \(0\)\
\-\ interrupted\\:\\ 0\\.08129812392712571\ \(0\)\
\-\ lifetime\\:\\ 0\\.08129812392712571\ \(0\)\
\-\ pcm\\:\\ 0\\.07915672145428522\ \(0\)\
\-\ 20\\:\\ 0\\.07854240364626446\ \(0\)\
\-\ years\\:\\ 0\\.07462812893229488\ \(0\)\
\-\ as\\:\\ 0\\.07336400269091448\ \(0\)\
\-\ neoplasia\\:\\ 0\\.07332442969072409\ \(0\)\
\-\ carcinoma\\:\\ 0\\.07282242753198734\ \(0\)\
\-\ characteristically\\:\\ 0\\.0727770673208042\ \(0\)\
\-\ include\\:\\ 0\\.07243723744367618\ \(0\)\
\-\ spared\\:\\ 0\\.07225641642077071\ \(0\)\
\-\ costophrenic\\:\\ 0\\.06997731879039844\ \(0\)\
\-\ manifestation\\:\\ 0\\.0691864958231401\ \(0\)\
\-\ risks\\:\\ 0\\.0691864958231401\ \(0\)\
\-\ common\\:\\ 0\\.06904342733363258\ \(0\)\
\-\ than\\:\\ 0\\.06901384665904894\ \(0\)\
\-\ predominately\\:\\ 0\\.06881202839606496\ \(0\)\
\-\ layer\\:\\ 0\\.06776155206785262\ \(0\)\
\-\ surgery\\:\\ 0\\.06545532533077138\ \(0\)\
\-\ pleura\\:\\ 0\\.06485968575675886\ \(0\)\
\-\ chest\\:\\ 0\\.0642632431873533\ \(0\)\
\-\ associated\\:\\ 0\\.06416880739922487\ \(0\)\
\-\ most\\:\\ 0\\.06335984660212493\ \(0\)\
\-\ other\\:\\ 0\\.06322419495925354\ \(0\)\
\-\ cr\\:\\ 0\\.06299912124573208\ \(0\)\
\-\ this\\:\\ 0\\.06275072306477816\ \(0\)\
\-\ sulci\\:\\ 0\\.06258058812638659\ \(0\)\
\-\ lower\\:\\ 0\\.06221188887346004\ \(0\)\
\-\ posterolateral\\:\\ 0\\.06217785253272078\ \(0\)\
\-\ collagen\\:\\ 0\\.06178976515912824\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.06003645005988029\ \(0\)\
\-\ contusion\\:\\ 0\\.05987597746222205\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.05987597746222205\ \(0\)\
\-\ excluded\\:\\ 0\\.05987597746222205\ \(0\)\
\-\ after\\:\\ 0\\.05906055303888177\ \(0\)\
\-\ requires\\:\\ 0\\.058960740268390426\ \(0\)\
\-\ effusions\\:\\ 0\\.05696652946224968\ \(0\)\
\-\ rib\\:\\ 0\\.055602390581720236\ \(0\)\
\-\ atelectasis\\:\\ 0\\.054204158296319166\ \(0\)\
\-\ followup\\:\\ 0\\.05374609541527841\ \(0\)\
\-\ incidence\\:\\ 0\\.052399906457648665\ \(0\)\
\-\ require\\:\\ 0\\.05232115165999094\ \(0\)\
\-\ must\\:\\ 0\\.05216536456258261\ \(0\)\
\-\ surface\\:\\ 0\\.05078886041224809\ \(0\)\
\-\ represent\\:\\ 0\\.05065377979023048\ \(0\)\
\-\ indicated\\:\\ 0\\.050066224428735165\ \(0\)\
\-\ round\\:\\ 0\\.04987734822993794\ \(0\)\
\-\ parietal\\:\\ 0\\.0491535979325674\ \(0\)\
\-\ mediastinal\\:\\ 0\\.0491535979325674\ \(0\)\
\-\ the\\:\\ 0\\.04858512531347546\ \(0\)\
\-\ absence\\:\\ 0\\.0485306970242889\ \(0\)\
\-\ respiratory\\:\\ 0\\.04842124758639202\ \(0\)\
\-\ located\\:\\ 0\\.048152436731828965\ \(0\)\
\-\ with\\:\\ 0\\.04767843272175778\ \(0\)\
\-\ base\\:\\ 0\\.04630462159704725\ \(0\)\
\-\ previous\\:\\ 0\\.04599656479691021\ \(0\)\
\-\ causes\\:\\ 0\\.04599656479691021\ \(0\)\
\-\ at\\:\\ 0\\.04598467274090224\ \(0\)\
\-\ malignancy\\:\\ 0\\.04557136007581708\ \(0\)\
\-\ 60\\:\\ 0\\.04552975680032348\ \(0\)\
\-\ greater\\:\\ 0\\.044846243161725995\ \(0\)\
\-\ early\\:\\ 0\\.04387884985132715\ \(0\)\
\-\ risk\\:\\ 0\\.04349457431083383\ \(0\)\
\-\ malignant\\:\\ 0\\.043392129748236245\ \(0\)\
\-\ sign\\:\\ 0\\.04214279513052527\ \(0\)\
\-\ cause\\:\\ 0\\.04146921571069397\ \(0\)\
\-\ less\\:\\ 0\\.04141260429597271\ \(0\)\
\-\ areas\\:\\ 0\\.041328246333761066\ \(0\)\
\-\ bilaterally\\:\\ 0\\.04059761092959786\ \(0\)\
\-\ often\\:\\ 0\\.039719341277813985\ \(0\)\
\-\ will\\:\\ 0\\.03917920792023858\ \(0\)\
\-\ diffuse\\:\\ 0\\.03817462941180523\ \(0\)\
\-\ his\\:\\ 0\\.03691773994305462\ \(0\)\
\-\ appearance\\:\\ 0\\.03669770685599894\ \(0\)\
\-\ however\\:\\ 0\\.036029438113557376\ \(0\)\
\-\ 10\\:\\ 0\\.03559518117999997\ \(0\)\
\-\ fracture\\:\\ 0\\.03459597441638197\ \(0\)\
\-\ these\\:\\ 0\\.03437472474987475\ \(0\)\
\-\ prior\\:\\ 0\\.034058304012505126\ \(0\)\
\-\ is\\:\\ 0\\.03334072800569762\ \(0\)\
\-\ symptoms\\:\\ 0\\.03330601635393032\ \(0\)\
\-\ increased\\:\\ 0\\.032916985667484334\ \(0\)\
\-\ bilateral\\:\\ 0\\.03271515976220055\ \(0\)\
\-\ man\\:\\ 0\\.03222668882953542\ \(0\)\
\-\ may\\:\\ 0\\.030632991406618317\ \(0\)\
\-\ case\\:\\ 0\\.030581711987192277\ \(0\)\
\-\ but\\:\\ 0\\.030101575821997788\ \(0\)\
\-\ be\\:\\ 0\\.024693563859182567\ \(0\)\
\-\ an\\:\\ 0\\.02327746244107919\ \(0\)\
\-\ ct\\:\\ 0\\.023174754943243257\ \(0\)\
\-\ or\\:\\ 0\\.021176479549340176\ \(0\)\
\-\ patient\\:\\ 0\\.019798787751735436\ \(0\)\
\-\ for\\:\\ 0\\.018450005623836613\ \(0\)\
\-\ to\\:\\ 0\\.015218020316844431\ \(0\)\
